ProCE Banner Activity

How Should We Individualize Management for Patients With Type 2 Diabetes and CKD?

Clinical Thought
Dr Vivian Fonseca provides insights on how to tailor the management of type 2 diabetes (T2D) and chronic kidney disease (CKD) for your individual patients, including treatment recommendations for high-risk patients and those with concurrent cardiovascular disease.

Released: September 14, 2022

Expiration: September 13, 2023

Share

Faculty

Vivian A. Fonseca

Vivian A. Fonseca, MD, FRCP

Tullis-Tulane Alumni Chair in Diabetes
Professor of Medicine
Chief, Section of Endocrinology
Tulane University School of Medicine
New Orleans, Louisiana

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by independent educational grants from

Bayer HealthCare Pharmaceuticals Inc

Boehringer Ingelheim and Eli Lilly

Faculty Disclosure

Primary Author

Vivian A. Fonseca, MD, FRCP

Tullis-Tulane Alumni Chair in Diabetes
Professor of Medicine
Chief, Section of Endocrinology
Tulane University School of Medicine
New Orleans, Louisiana

Vivian Fonseca, MD, FRCP: research support (paid to institution): Fractyl, Jaguar Gene Therapy; constultant/speaker: Abbott, Asahi Astra-Zeneca, Novo Nordisk, Sanofi; stock/stock options: Abbott, Amgen, BRAVO4Health, Mellitus Health; patent: BRAVO Risk Engine for Predicting Diabetes Complications.